Cargando…

Mitochondria in Cell-Based Therapy for Stroke

Despite a relatively developed understanding of the pathophysiology underlying primary and secondary mechanisms of cell death after ischemic injury, there are few established treatments to improve stroke prognoses. A major contributor to secondary cell death is mitochondrial dysfunction. Recent adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Monsour, Molly, Gordon, Jonah, Lockard, Gavin, Alayli, Adam, Borlongan, Cesar V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854436/
https://www.ncbi.nlm.nih.gov/pubmed/36671040
http://dx.doi.org/10.3390/antiox12010178
_version_ 1784873119227314176
author Monsour, Molly
Gordon, Jonah
Lockard, Gavin
Alayli, Adam
Borlongan, Cesar V.
author_facet Monsour, Molly
Gordon, Jonah
Lockard, Gavin
Alayli, Adam
Borlongan, Cesar V.
author_sort Monsour, Molly
collection PubMed
description Despite a relatively developed understanding of the pathophysiology underlying primary and secondary mechanisms of cell death after ischemic injury, there are few established treatments to improve stroke prognoses. A major contributor to secondary cell death is mitochondrial dysfunction. Recent advancements in cell-based therapies suggest that stem cells may be revolutionary for treating stroke, and the reestablishment of mitochondrial integrity may underlie these therapeutic benefits. In fact, functioning mitochondria are imperative for reducing oxidative damage and neuroinflammation following stroke and reperfusion injury. In this review, we will discuss the role of mitochondria in establishing the anti-oxidative effects of stem cell therapies for stroke.
format Online
Article
Text
id pubmed-9854436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98544362023-01-21 Mitochondria in Cell-Based Therapy for Stroke Monsour, Molly Gordon, Jonah Lockard, Gavin Alayli, Adam Borlongan, Cesar V. Antioxidants (Basel) Review Despite a relatively developed understanding of the pathophysiology underlying primary and secondary mechanisms of cell death after ischemic injury, there are few established treatments to improve stroke prognoses. A major contributor to secondary cell death is mitochondrial dysfunction. Recent advancements in cell-based therapies suggest that stem cells may be revolutionary for treating stroke, and the reestablishment of mitochondrial integrity may underlie these therapeutic benefits. In fact, functioning mitochondria are imperative for reducing oxidative damage and neuroinflammation following stroke and reperfusion injury. In this review, we will discuss the role of mitochondria in establishing the anti-oxidative effects of stem cell therapies for stroke. MDPI 2023-01-12 /pmc/articles/PMC9854436/ /pubmed/36671040 http://dx.doi.org/10.3390/antiox12010178 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Monsour, Molly
Gordon, Jonah
Lockard, Gavin
Alayli, Adam
Borlongan, Cesar V.
Mitochondria in Cell-Based Therapy for Stroke
title Mitochondria in Cell-Based Therapy for Stroke
title_full Mitochondria in Cell-Based Therapy for Stroke
title_fullStr Mitochondria in Cell-Based Therapy for Stroke
title_full_unstemmed Mitochondria in Cell-Based Therapy for Stroke
title_short Mitochondria in Cell-Based Therapy for Stroke
title_sort mitochondria in cell-based therapy for stroke
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854436/
https://www.ncbi.nlm.nih.gov/pubmed/36671040
http://dx.doi.org/10.3390/antiox12010178
work_keys_str_mv AT monsourmolly mitochondriaincellbasedtherapyforstroke
AT gordonjonah mitochondriaincellbasedtherapyforstroke
AT lockardgavin mitochondriaincellbasedtherapyforstroke
AT alayliadam mitochondriaincellbasedtherapyforstroke
AT borlongancesarv mitochondriaincellbasedtherapyforstroke